These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29951752)

  • 1. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples.
    Oono Y; Kuwata T; Takashima K; Shinmura K; Hori K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
    Gastric Cancer; 2019 Mar; 22(2):335-343. PubMed ID: 29951752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
    Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer.
    García I; Vizoso F; Martín A; Sanz L; Abdel-Lah O; Raigoso P; García-Muñiz JL
    Ann Surg Oncol; 2003 Apr; 10(3):234-41. PubMed ID: 12679307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
    Gumusay O; Benekli M; Ekinci O; Baykara M; Ozet A; Coskun U; Demirci U; Uner A; Dursun A; Atak EY; Buyukberber S
    Jpn J Clin Oncol; 2015 May; 45(5):416-21. PubMed ID: 25732909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
    Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
    Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
    Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
    Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
    Zhang J; Guo L; Liu X; Li W; Ying J
    Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.
    Oono Y; Kuwata T; Takashima K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
    Surg Endosc; 2018 Sep; 32(9):3964-3971. PubMed ID: 29500656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ROS1 rearrangement in gastric adenocarcinoma.
    Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
    Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
    Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
    Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
    Kimura M; Tsuda H; Morita D; Shinto E; Tanimoto T; Ichikura T; Mochizuki H; Matsubara O
    Jpn J Clin Oncol; 2005 Jun; 35(6):324-31. PubMed ID: 15928192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
    Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
    Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.